Compound and application thereof in preparation of medicine for treating enterovirus related diseases

CN118922415APending Publication Date: 2024-11-08SHANGHAI TECH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380028365.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-11
Filing Date
2023-04-11
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing technology lacks effective specific drugs to treat diseases caused by enteroviruses. In particular, the high mutation rate and multiple serotypes of enteroviruses make vaccine development difficult. Existing inhibitors such as AG7088 have low bioavailability and Unsuccessful commercialization.

Method used

A compound, ST-0101 and ST-0102, was developed that significantly inhibits the activity of multiple enterovirus 3C proteases by reversibly binding to the cysteine ​​residues of HRV 3C protease, and through in vitro enzyme activity experiments and protein complexes Crystal structure analysis verified its therapeutic potential.

Benefits of technology

ST-0101 and ST-0102 can significantly inhibit the activity of 3C protease caused by rhinovirus, poliovirus, enterovirus, etc., filling the gap in the existing technology that lacks specific drugs for human enterovirus, and provide a broad-spectrum Anti-enteroviral treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922415A_ABST
    Figure CN118922415A_ABST
Patent Text Reader

Abstract

The invention discloses a compound and application thereof in preparation of a medicine for treating enterovirus related diseases. The compound is a compound with a general formula shown in a formula I, and the 3C protease activity of various enteroviruses can be remarkably inhibited. At present, no specific medicine which is approved to appear on the market and aims at the human enterovirus exists, and the defects in the prior art can be overcome by using the scheme of the invention. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

A compound and its use in preparing medicine for treating enterovirus-related diseases Technical Field

[0001] The present invention belongs to the field of virus treatment and relates to a compound and its application in preparing medicines for treating enterovirus-related diseases. Background Art

[0002] Enterovirus is a ubiquitous virus with a wide variety of infections. The enterovirus genus belongs to the Picornaviridae family, which includes poliovirus, coxsackievirus, echovirus, enterovirus, and rhinovirus. 1 Enterovirus is mainly transmitted through fecal-oral transmission and droplet transmission. Common symptoms of enterovirus infection are mild respiratory diseases (common colds), so they are often ignored by people. However, as the most common infectious disease in humans, it can also cause serious diseases such as poliomyelitis, aseptic meningitis, conjunctivitis, pericarditis, hand, foot and mouth disease and even paralysis. 2,3 With the exception of the poliovirus vaccine, there are no commercially available vaccines or effective medications for these common viruses.

[0003] The genome of enterovirus is a single-stranded positive-sense RNA with a length of about 7.5kb, which mainly encodes the structural proteins required for virus packaging and non-structural proteins related to replication and transcription. Due to the low-fidelity replication and frequent recombination of enterovirus, it has a high mutation rate. 4 The polyprotein encoded by the enterovirus open reading frame can be divided into three regions P1-P3, of which the P1 region contains four structural proteins (VP1-VP4), and the P2 and P3 regions contain seven non-structural proteins (2A-2C and 3A-3D). Only when these functional subunits are cut into independent protein units by the virus-encoded protease can the virus complete normal transcription and replication. After the host cell is infected by the virus, the first region to be translated is the P1 region encoding the capsid structural protein. Subsequently, during the translation process of the P2 and P3 regions, 2A and 3C will be released from the polyprotein and be responsible for the cleavage of the viral polyprotein. The 2A protease has two cleavage sites, while the 3C protease has 8 cleavage sites. 5 It can be seen that 3C protease plays a key regulatory role in the transcription and replication of the virus, and therefore has become the focus of research. 6 Enterovirus 3C protease is a multifunctional cysteine ​​protease that belongs to the chymotrypsin-related endopeptidase family of proteases. 7 Among different species of enteroviruses, 3C proteases share approximately 50–75% sequence similarity.6 The amino acid residues of the catalytic triad are completely conserved across the enterovirus genus. Furthermore, the amino acid residues surrounding the catalytic residues are more conserved than those in the rest of the protein, suggesting similar mechanisms involved in sequence specificity and cleavage among enteric proteases.

[0004] Rhinovirus (HRV) is the most well-known of the enteroviruses due to its seasonality and prevalence, and it often causes a variety of complications in children, the elderly, and people with weakened immune systems. 8 HRV infection can cause up to 80% of viral asthma exacerbations and is responsible for up to 16 deaths per week in Australia and 25 deaths per week in the United States. 9 Although poliovirus has been eradicated by vaccines, the development of HRV vaccines is not feasible due to the large number of HRV serotypes (over 100). AG7088 is a 3C protease inhibitor that has significant antiviral activity against multiple human rhinovirus serotypes and has negligible inhibitory activity against mammalian cysteine ​​and serine proteases (including cathepsin B, elastase, chymotrypsin, trypsin, thrombin, and calpain). 10 However, due to the low bioavailability of AG7088, scientists have been trying to develop a specific drug based on its theory for many years, but no successful drug has been developed so far. 11 .

[0005] Summary of the Invention

[0006] To address the problem of the lack of specific drugs for diseases caused by enterovirus in the prior art, the present invention provides a compound and its use in the preparation of a medicament for treating enterovirus-related diseases. The object of the present invention is to provide a treatment regimen for diseases caused by enterovirus infection. ST-0101 and ST-0102 of the present invention can be used to treat diseases caused by rhinovirus, as well as major infectious diseases caused by other enterovirus viruses, such as poliovirus, coxsackievirus, echovirus, enterovirus, etc. ST-0101 and ST-0102 (shown in Figure 1) can reversibly bind to the cysteine ​​residue (C147) of HRV 3C protease. Through in vitro enzyme activity experiments and protein complex crystal structure analysis, the present invention found that ST-0101 and ST-0102 can be used to treat related diseases caused by enterovirus.

[0007] In order to solve the above technical problems, the first aspect of the present invention provides a compound, which is a compound of the general formula shown in the following formula I:

[0008] wherein R1 is selected from:

[0009] R2, R3 and R4 are selected from H and halogen.

[0010] In some preferred embodiments, in the compound, when R1 is When Ar is 3,4-(OCH2)C6H3, 4-Me2NC6H4, C6H5, 4-MeC6H4, 4-Cl, 2-FC6H3 or 5-Methyl-3-isoxazole; R2, R3 and R4 are H, F or CF3.

[0011] In some more preferred embodiments, the compound is a compound represented by Formula II or Formula III:

[0012] To solve the above technical problems, the second aspect of the present invention provides a pharmaceutical composition, which comprises the compound or a pharmaceutically acceptable salt thereof as described in the first aspect of the present invention; preferably also comprises a pharmaceutically acceptable diluent or carrier.

[0013] To solve the above technical problems, the third aspect of the present invention provides the use of the compound described in the first aspect of the present invention or the pharmaceutical composition described in the second aspect of the present invention in the preparation of an inhibitor of enterovirus protease.

[0014] In some preferred embodiments, the Enterovirus protease is selected from 2A protease, 2B protease, 2C protease, 3A protease, 3B protease, 3C protease and 3D protease; and / or, the Enterovirus protease is a protease of rhinovirus, poliovirus, coxsackievirus, echovirus or enterovirus.

[0015] In some more preferred embodiments, the enterovirus protease is a 3C protease of a rhinovirus, poliovirus, coxsackievirus, echovirus, or enterovirus.

[0016] Preferably, the 3C protease is the 3C protease of rhinovirus HRV-A2 or HRV-B14, poliovirus type 1, enterovirus EV71, echovirus 1 or coxsackievirus CVB3.

[0017] To solve the above technical problems, the fourth aspect of the present invention provides the use of the compound described in the first aspect of the present invention or the pharmaceutical composition described in the second aspect of the present invention in the preparation of a drug for treating intestinal-related diseases.

[0018] In some preferred embodiments, the intestinal-related disease is a disease caused by enterovirus.

[0019] Preferably, the enterovirus genus includes rhinovirus, poliovirus, coxsackievirus, echovirus and enterovirus.

[0020] In some more preferred embodiments, the rhinovirus includes HRV-A2 and HRV-B14, the coxsackievirus includes CVB3, the echovirus includes Echovirus1, the enterovirus includes EV71, and the poliovirus includes Poliovirus type 1.

[0021] To solve the above technical problems, the fifth aspect of the present invention provides a method for treating or preventing intestinal-related diseases, which comprises administering an effective amount of the compound as described in the first aspect of the present invention or the pharmaceutical composition as described in the second aspect of the present invention to a subject in need.

[0022] In some preferred embodiments, the intestinal-related disease is a disease caused by enterovirus.

[0023] Preferably, the enterovirus genus includes rhinovirus, poliovirus, coxsackievirus, echovirus and enterovirus.

[0024] More preferably, the rhinovirus includes HRV-A2 and HRV-B14, the coxsackievirus includes CVB3, the echovirus includes Echovirus1, the enterovirus includes EV71, and the poliovirus includes Poliovirus type 1.

[0025] In some preferred embodiments, the present invention further comprises administering other drugs for treating or preventing intestinal diseases.

[0026] Preferably, the other drug is an inhibitor of 3C protease.

[0027] More preferably, the inhibitor of 3C protease comprises AG7088 or other AG7088 derivatives other than the compound described in the first aspect of the present invention.

[0028] To address the above technical issues, the sixth aspect of the present invention provides a non-diagnostic in vitro method for inhibiting or detecting 3C protease, or a method for inhibiting or detecting 3C protease in vivo; the method comprises contacting the 3C protease with an effective amount of the compound described in the first aspect of the present invention or the pharmaceutical composition described in the second aspect of the present invention. Application scenarios for non-diagnostic in vitro methods for inhibiting or detecting 3C protease include, for example, scientific research, where a compound described in the present invention is contacted with a sample in a laboratory to determine whether the sample contains the 3C protease.

[0029] In some preferred embodiments, the 3C protease is the 3C protease of rhinovirus, poliovirus, coxsackievirus, echovirus or enterovirus.

[0030] The positive progress effect of the present invention is:

[0031] The compounds disclosed herein, such as those represented by Formula II or Formula III, can significantly inhibit the 3C protease activity of various enteroviruses. Currently, there are no approved specific drugs for human enteroviruses. Using compounds represented by Formula II or Formula III to treat enteric-related diseases could address the shortcomings of existing technologies. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 shows the molecular formulas of ST-0101 and ST-0102.

[0033] FIG2 shows that both ST-0101 and ST-0102 have significant inhibitory activity against rhinovirus HRV-A2 3C protease.

[0034] FIG3 shows that ST-0101 has significant inhibitory activity against rhinovirus HRV-B14 3C protease.

[0035] FIG4 shows that ST-0101 and ST-0102 have significant inhibitory activity against poliovirus type 1 3C protease.

[0036] FIG5 shows that ST-0101 and ST-0102 have significant inhibitory activity against enterovirus EV71 3C protease.

[0037] FIG6 shows that ST-0101 and ST-0102 have significant inhibitory activity against Echovirus 1 3C protease.

[0038] FIG7 shows that ST-0101 and ST-0102 have significant inhibitory activity against Coxsackievirus CVB3 3C protease.

[0039] FIG8 shows the reversible covalent interaction of HRV 3C protease with the inhibitor ST0102. DETAILED DESCRIPTION

[0040] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.

[0041] Example 1

[0042] In vitro enzyme activity experiments revealed that ST-0101 and ST-0102 can significantly inhibit the 3C protease activity of rhinovirus (HRV-A2, HRV-B14), poliovirus (type 1), enterovirus (EV71), echovirus (Echovirus1), and coxsackievirus (CVB3) (Figures 2 to 7).

[0043] The fluorescent substrate used to determine the inhibitory effects of ST-0101 and ST-0102 on the 3C protease of the aforementioned viruses was Dabcyl-Leu-Glu-Val-Leu-Phe-Gln-Gly-Pro-Lys(5-FAM)-NH2 (SEQ ID NO: 3). The amino acid sequence of the substrate was designed primarily based on the canonical recognition sequence of 3C protease. The fluorescent group 5-FAM and the quencher group Dabcyl are attached to either end of the short peptide. When 3C protease cleaves the short peptide, the quencher and fluorescent groups separate, and a fluorescent signal from the fluorescent group can be detected. Therefore, when 3C protease reacts with the substrate, the rate of increase in fluorescence intensity can reflect the enzymatic reaction rate of 3C protease. When different concentrations of the inhibitory molecule are added, the enzyme activity is inhibited to varying degrees, and the rate of increase in fluorescence intensity is also suppressed. The IC50 curve for the inhibitor is generated by measuring the corresponding enzyme activity when different concentrations of inhibitor are added, with the fluorescence increase rate in the absence of inhibitor molecules being defined as 100% enzyme activity and the fluorescence increase rate in the absence of enzyme being defined as 0% enzyme activity (the substrate molecules may degrade at a very slow rate). The buffer system used in this experiment was 20mM Tris pH 8.0, 150mM NaCl, 0.1mg / ml BSA (bovine serum albumin), 0.01% (v / v) Triton X-100, the substrate concentration used was 20μM, and the protein concentration used was 0.5μM.

[0044] HRV-A2 3C amino acid sequence (SEQ ID NO: 1):

[0045] HRV-B14 3C amino acid sequence (SEQ ID NO: 2):

[0046] Poliovirus type 1 3C amino acid sequence (SEQ ID NO: 4):

[0047] EV71 3C amino acid sequence (SEQ ID NO: 5):

[0048] Echovirus 1 3C amino acid sequence (SEQ ID NO: 6):

[0049] CVB3 3C amino acid sequence (SEQ ID NO: 7):

[0050] Example 2

[0051] The present invention has resolved the 1.54 angstrom high-resolution structure of HRV 3C protease and the inhibitor ST-0102. As shown in Figure 8, a reversible covalent interaction is observed between C147 at the protease active center and the inhibitor. Crystals of the HRV 3C protease and ST-0102 complex were obtained by sessile drop method screening using the Hampton Research Index kit. X-ray diffraction data were collected at the Shanghai Synchrotron Radiation Facility. The crystal diffraction data were processed using the XDS software package. Using 5FX6 from the RCSB database as the corresponding initial model, molecular replacement was performed using the Phenix.phaser program. Phenix.refine and Coot software were used for repeated cross-correction, ultimately yielding the high-resolution structure of the HRV 3C protease and ST-0102 complex.

[0052] Because the substrate binding pocket of enterovirus 3C protease is highly conserved, inhibitors targeting this binding pocket (ST-0101 & ST-0102) have broad-spectrum anti-enteroviral activity. ST-0101 & ST-0102 of the present invention can be used to treat major infectious diseases caused by rhinovirus, poliovirus, coxsackievirus, echovirus, enterovirus, and others.

[0053] Although the above describes specific embodiments of the present invention, it should be understood by those skilled in the art that these are merely illustrative and that various changes or modifications may be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.

[0054] References:

[0055] 1. OS Nikonov, ES Chernykh, MB Garber, EY Nikonova, Enteroviruses: Classification, Diseases They Cause, and Approaches to Development of Antiviral Drugs. Biochemistry (Mosc) 82, 1615-1631 (2017).

[0056] 2. L. Royston, C. Tapparel, Rhinoviruses and Respiratory Enteroviruses: Not as Simple as ABC. Viruses 8, (2016).

[0057] 3.B.Jubelt,HLLipton,Enterovirus / picornavirus infections.Handb Clin Neurol 123,379-416(2014).

[0058] 4. M. Nikolaidis et al., Large-scale genomic analysis reveals recurrent patterns of intertypic recombination in human enteroviruses. Virology 526, 72-80 (2019).

[0059] 5.OHLaitinen et al., Enteroviral proteases: structure, host interactions and pathogenicity. Rev Med Virol 26, 251-267 (2016).

[0060] 6.M.Laajala,D.Reshamwala,V.Marjomaki,Therapeutic targets for enterovirus infections.Expert Opin Ther Tar 24,745-757(2020).

[0061] 7.J.Seipelt et al.,The structures of picornaviral proteinases.Virus Res 62,159-168(1999).

[0062] 8.C.Esneau,A.C.Duff,N.W.Bartlett,Understanding Rhinovirus Circulation and Impact on Illness.Viruses 14,(2022).

[0063] 9.L.M.Jensen,E.J.Walker,D.A.Jans,R.Ghildyal,Proteases of human rhinovirus:role in infection.Methods Mol Biol 1221,129-141(2015).

[0064] 10.D.A.Matthews et al.,Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.Proc Natl Acad Sci U S A 96,11000-11007(1999).

[0065] 11.K.Namoto et al.,Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.Bioorg Med Chem Lett 28,906-909(2018).

Claims

1. A compound, characterized in that It is a compound of the general formula shown in the following formula I: wherein R1 is selected from: R2, R3 and R4 are selected from H and halogen.

2. The compound according to claim 1, wherein In the compound, when R1 is When Ar is 3,4-(OCH2)C6H3, 4-Me2NC6H4, C6H5, 4-MeC6H4, 4-Cl, 2-FC6H3 or 5-Methyl-3-isoxazole; R2, R3 and R4 are H, F or CF3.

3. The compound according to claim 1, wherein It is a compound represented by formula II or formula III:

4. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof.

5. The pharmaceutical composition according to claim 4, wherein A pharmaceutically acceptable diluent or carrier is also included.

6. Use of the compound according to any one of claims 1 to 3 or the pharmaceutical composition according to claim 4 or 5 in the preparation of an inhibitor of enterovirus protease.

7. The use according to claim 6, characterized in that The enterovirus protease is selected from 2A protease, 2B protease, 2C protease, 3A protease, 3B protease, 3C protease and 3D protease; and / or, the enterovirus protease is a protease of rhinovirus, poliovirus, coxsackievirus, echovirus or enterovirus.

8. The use according to claim 7, characterized in that The enterovirus protease is 3C protease of rhinovirus, poliovirus, coxsackievirus, echovirus or enterovirus.

9. The use according to claim 8, characterized in that The 3C protease is the 3C protease of rhinovirus HRV-A2 or HRV-B14, poliovirus type 1, enterovirus EV71, echovirus 1 or coxsackievirus CVB3.

10. Use of the compound according to any one of claims 1 to 3 or the pharmaceutical composition according to claim 4 or 5 in the preparation of a medicament for treating intestinal-related diseases.

11. The use according to claim 10, characterized in that The intestinal related diseases are diseases caused by enterovirus.

12. The use according to claim 11, characterized in that The enterovirus genus includes rhinovirus, poliovirus, coxsackievirus, echovirus and enterovirus.

13. The use according to claim 12, characterized in that The rhinovirus includes HRV-A2 and HRV-B14, the coxsackievirus includes CVB3, the echovirus includes Echovirus1, the enterovirus includes EV71, and the poliovirus includes Poliovirus type 1.

14. A method for inhibiting or detecting 3C protease in vitro for non-diagnostic purposes, comprising contacting the 3C protease in vitro with an effective amount of the compound according to any one of claims 1 to 3 or the pharmaceutical composition according to claim 4 or 5.

15. The method of claim 14, wherein the 3C protease is a 3C protease of a rhinovirus, poliovirus, coxsackievirus, echovirus, or enterovirus.